Mallinckrodt (MNK) PT, Estimates Lowered at Leerink Partners Following Mixed Q3
Get Alerts MNK Hot Sheet
Rating Summary:
6 Buy, 14 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Leerink Partners analyst Jason Gerberry lowered estimates and his price target on Market Perform-rated Mallinckrodt plc (NYSE: MNK) to $112.00 (from $133.00) following mixed Q3 results that included a ~$20m miss on consensus due to weaker than expected Acthar (autoimmune disease) and oxycodone Gx sales.
Gerberry commented, "While the F'3Q topline miss was relatively modest, our new model includes much more conservative forecasts for Acthar following mgmt.'s revised outlook for slower product growth. In addition, while MNK's Xartemis XR was clearly struggling to gain traction in the pain market, the decision to stop promoting the drug (as well as future promotion of MNK-155) largely eliminates two high margin contributors from our model. Our updated F'16 EPS of $7.87 backs out contribution from the recently divested contrast imaging and takes into account our lower sales forecasts. We now forecast F'15-17 and F'15-21 EPS CAGR's of 9% and 7%, compared to 15% and 13%, respectively. We are lowering our PT to $112/share (from $133) reflecting lower EPS & multiple compression. We remain MP."
For an analyst ratings summary and ratings history on Mallinckrodt plc click here. For more ratings news on Mallinckrodt plc click here.
Shares of Mallinckrodt plc closed at $106.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
- Talen Energy Corp (TLNE) PT Raised to $120 at BWS Financial
- Hyundai Mobis Co Ltd. (012330:KS) PT Raised to KRW340,000 at HSBC
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!